Cabotegravir Plus Rilpivirine: First Approval
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the treatment of HIV-1 infection in adults to replace current antiretroviral therapy in patients who are virologically stable and suppressed. This article summarizes the milestones in the development of co-packaged cabotegravir and rilpivirine leading to this first approval.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the last 14 years, four more INSTIs were approved for treatment of HIV infection: elvitegravir, dolutegravir, bictegravir and cabotegravir147–150.”
From Structure and function of retroviral integrase (2022) · cites this paper as [150]
Citations
Cites
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V., Bredeek, F., Smith, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1904398 · Cited by 594
Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 499
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P.-M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1909512 · Cited by 487
Margolis, D. A., Brinson, C. C., Smith, G. H. R., de Vente, J., Hagins, D. P., Eron, J. J., Griffith, S. K., Clair, M. H. S., Stevens, M. C., Williams, P. E., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00152-8 · Cited by 204
Spreen, W., Ford, S. L., Chen, S., Wilfret, D., Margolis, D., Gould, E., & Piscitelli, S. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000301 · Cited by 146
Spreen, W., Min, S., Ford, S. L., Chen, S., Lou, Y., Bomar, M., St Clair, M., Piscitelli, S., & Fujiwara, T. (2013) · HIV Clinical Trials · doi:10.1310/hct1405-192 · Cited by 114
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Spreen, W., Williams, P., Margolis, D., Ford, S. L., Crauwels, H., Lou, Y., Gould, E., Stevens, M., & Piscitelli, S. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000365 · Cited by 112
Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Ford, S. L., Sutton, K., Lou, Y., Zhang, Z., Tenorio, A., Trezza, C., Patel, P., & Spreen, W. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-17 · Cited by 46
In VitroAntiviral Activity of Cabotegravir against HIV-2
Smith, R. A., Wu, V. H., Zavala, C. G., Raugi, D. N., Ba, S., Seydi, M., & Gottlieb, G. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01299-18 · Cited by 25
Research works printed but not linked: 2
- Overton ET, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study [abstract no.34]. In: Conference on Retroviruses and Opportunistic Infections. 2020.
- Orkin C. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results [abstract no. 482-PS]. In: Conference on Retroviruses and Opportunistic Infections. 2020.
Cited by
Fluorine-containing drugs approved by the FDA in 2021
He, J., Li, Z., Dhawan, G., Zhang, W., Sorochinsky, A. E., Butler, G., Soloshonok, V. A., & Han, J. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.001 · Cited by 172
Approved Nanomedicine against Diseases
Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030774 · Cited by 203
Jaeger, H., Overton, E. T., Richmond, G., Rizzardini, G., Andrade-Villanueva, J. F., Mngqibisa, R., Hermida, A. O., Thalme, A., Belonosova, E., Ajana, F., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00185-5 · Cited by 142
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Long-acting parenteral drug delivery systems for the treatment of chronic diseases
Jindal, A. B., Bhide, A. R., Salave, S., Rana, D., & Benival, D. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114862 · Cited by 119
Metadata
- Authors
- Markham, A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Markham, A.
- Venue
- Drugs
- Published
- 2020-06
- Volume
- 80
- Issue
- 9
- Pages
- 915-922
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3031948545
- Cited by
- 54
- References
- 13
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 8 · 2023: 17 · 2022: 13 · 2021: 9 · 2020: 1
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- cabotegravir, rilpivirine, HIV-1 infection, antiretroviral therapy, long-acting injectables, drug approval, ATLAS trial
- MeSH terms
- Rilpivirine, Adult, Drug Therapy, Combination, Humans, Molecular Conformation, Pyridones, HIV-1, HIV Infections, Drug Approval, Anti-HIV Agents, Diketopiperazines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cabotegravir Plus Rilpivirine: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01326-8
- The paper
- Markham, A. (2020). Cabotegravir Plus Rilpivirine: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01326-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.